Ellen Scotton, Bárbara Antqueviezc, Mailton França de Vasconcelos, Giovana Dalpiaz, Luiza Paul Géa, Jéferson Ferraz Goularte, Rafael Colombo, Adriane Ribeiro Rosa. Biochem Pharmacol 2022
Times Cited: 1
Times Cited: 1
Times Cited
Times Co-cited
Similarity
The effectiveness of (R)-ketamine and its mechanism of action differ from those of (S)-ketamine in a chronic unpredictable mild stress model of depression in C57BL/6J mice.
Anna Rafało-Ulińska, Agnieszka Pałucha-Poniewiera. Behav Brain Res 2022
Anna Rafało-Ulińska, Agnieszka Pałucha-Poniewiera. Behav Brain Res 2022
100
Molecular Basis of Late-Life Depression.
Chien-Yi Kuo, Chieh-Hsin Lin, Hsien-Yuan Lane. Int J Mol Sci 2021
Chien-Yi Kuo, Chieh-Hsin Lin, Hsien-Yuan Lane. Int J Mol Sci 2021
100
Depression in multiple sclerosis: Is one approach for its management enough?
C Danielle Jones, Robert Motl, Brian M Sandroff. Mult Scler Relat Disord 2021
C Danielle Jones, Robert Motl, Brian M Sandroff. Mult Scler Relat Disord 2021
100
An update on ketamine and its two enantiomers as rapid-acting antidepressants.
Kai Zhang, Kenji Hashimoto. Expert Rev Neurother 2019
Kai Zhang, Kenji Hashimoto. Expert Rev Neurother 2019
100
Association between depression and the subsequent risk of Parkinson's disease: A meta-analysis.
Shun Wang, Shanping Mao, Dan Xiang, Congcong Fang. Prog Neuropsychopharmacol Biol Psychiatry 2018
Shun Wang, Shanping Mao, Dan Xiang, Congcong Fang. Prog Neuropsychopharmacol Biol Psychiatry 2018
100
Protocol for the MPTP mouse model of Parkinson's disease.
Vernice Jackson-Lewis, Serge Przedborski. Nat Protoc 2007
Vernice Jackson-Lewis, Serge Przedborski. Nat Protoc 2007
100
Comparison of (R)-ketamine and lanicemine on depression-like phenotype and abnormal composition of gut microbiota in a social defeat stress model.
Youge Qu, Chun Yang, Qian Ren, Min Ma, Chao Dong, Kenji Hashimoto. Sci Rep 2017
Youge Qu, Chun Yang, Qian Ren, Min Ma, Chao Dong, Kenji Hashimoto. Sci Rep 2017
100
Pilot randomized active-placebo-controlled trial of low-dose ketamine for the treatment of multiple sclerosis-related fatigue.
Kathryn C Fitzgerald, Bridget Morris, Aurash Soroosh, Alexandra Balshi, Dermot Maher, Adam Kaplin, Bardia Nourbakhsh. Mult Scler 2021
Kathryn C Fitzgerald, Bridget Morris, Aurash Soroosh, Alexandra Balshi, Dermot Maher, Adam Kaplin, Bardia Nourbakhsh. Mult Scler 2021
100
The Possible Application of Ketamine in the Treatment of Depression in Alzheimer's Disease.
Islam Mohammad Shehata, Waniyah Masood, Nouran Nemr, Alexandra Anderson, Kamal Bhusal, Amber N Edinoff, Elyse M Cornett, Adam M Kaye, Alan D Kaye. Neurol Int 2022
Islam Mohammad Shehata, Waniyah Masood, Nouran Nemr, Alexandra Anderson, Kamal Bhusal, Amber N Edinoff, Elyse M Cornett, Adam M Kaye, Alan D Kaye. Neurol Int 2022
100
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.
Samuel T Wilkinson, Elizabeth D Ballard, Michael H Bloch, Sanjay J Mathew, James W Murrough, Adriana Feder, Peter Sos, Gang Wang, Carlos A Zarate, Gerard Sanacora. Am J Psychiatry 2018
Samuel T Wilkinson, Elizabeth D Ballard, Michael H Bloch, Sanjay J Mathew, James W Murrough, Adriana Feder, Peter Sos, Gang Wang, Carlos A Zarate, Gerard Sanacora. Am J Psychiatry 2018
100
Use of subcutaneous ketamine to rapidly improve severe treatment-resistant depression in a patient with Alzheimer's disease.
Fabio Lopes Rocha, Ulisses Gabriel de Vasconcelos Cunha, Roberta Campos Paschoalin, Cláudia Hara, Débora Pereira Thomaz. Int Clin Psychopharmacol 2021
Fabio Lopes Rocha, Ulisses Gabriel de Vasconcelos Cunha, Roberta Campos Paschoalin, Cláudia Hara, Débora Pereira Thomaz. Int Clin Psychopharmacol 2021
100
Use of Ketamine in Elderly Patients with Treatment-Resistant Depression.
Carolina Medeiros da Frota Ribeiro, Patricio Riva-Posse. Curr Psychiatry Rep 2017
Carolina Medeiros da Frota Ribeiro, Patricio Riva-Posse. Curr Psychiatry Rep 2017
100
Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine.
Kenichi Fukumoto, Hidetoh Toki, Michihiko Iijima, Takashi Hashihayata, Jun-Ichi Yamaguchi, Kenji Hashimoto, Shigeyuki Chaki. J Pharmacol Exp Ther 2017
Kenichi Fukumoto, Hidetoh Toki, Michihiko Iijima, Takashi Hashihayata, Jun-Ichi Yamaguchi, Kenji Hashimoto, Shigeyuki Chaki. J Pharmacol Exp Ther 2017
100
Multiple sclerosis with severe pain and allodynia alleviated by oral ketamine.
Tetsuya Sakai, Shiro Tomiyasu, Takeshi Ono, Hiroyuki Yamada, Koji Sumikawa. Clin J Pain 2004
Tetsuya Sakai, Shiro Tomiyasu, Takeshi Ono, Hiroyuki Yamada, Koji Sumikawa. Clin J Pain 2004
100
Bone mineral density and incidence of stroke: European prospective investigation into cancer-norfolk population-based study, systematic review, and meta-analysis.
Phyo Kyaw Myint, Allan B Clark, Chun Shing Kwok, Yoon Kong Loke, Jessica Ka-Yan Yeong, Robert N Luben, Nicholas J Wareham, Kay-Tee Khaw. Stroke 2014
Phyo Kyaw Myint, Allan B Clark, Chun Shing Kwok, Yoon Kong Loke, Jessica Ka-Yan Yeong, Robert N Luben, Nicholas J Wareham, Kay-Tee Khaw. Stroke 2014
100
(R)-Ketamine Shows Greater Potency and Longer Lasting Antidepressant Effects Than Its Metabolite (2R,6R)-Hydroxynorketamine.
Chun Yang, Youge Qu, Masahito Abe, Dai Nozawa, Shigeyuki Chaki, Kenji Hashimoto. Biol Psychiatry 2017
Chun Yang, Youge Qu, Masahito Abe, Dai Nozawa, Shigeyuki Chaki, Kenji Hashimoto. Biol Psychiatry 2017
100
Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor.
Yan Wei, Lijia Chang, Kenji Hashimoto. Mol Psychiatry 2022
Yan Wei, Lijia Chang, Kenji Hashimoto. Mol Psychiatry 2022
100
Ketamine: A tale of two enantiomers.
Luke A Jelen, Allan H Young, James M Stone. J Psychopharmacol 2021
Luke A Jelen, Allan H Young, James M Stone. J Psychopharmacol 2021
100
Splenic NKG2D confers resilience versus susceptibility in mice after chronic social defeat stress: beneficial effects of (R)-ketamine.
Kai Zhang, Akemi Sakamoto, Lijia Chang, Youge Qu, Siming Wang, Yaoyu Pu, Yunfei Tan, Xingming Wang, Yuko Fujita, Tamaki Ishima,[...]. Eur Arch Psychiatry Clin Neurosci 2021
Kai Zhang, Akemi Sakamoto, Lijia Chang, Youge Qu, Siming Wang, Yaoyu Pu, Yunfei Tan, Xingming Wang, Yuko Fujita, Tamaki Ishima,[...]. Eur Arch Psychiatry Clin Neurosci 2021
100
Ketamine Therapy for Treatment-resistant Depression in a Patient with Multiple Sclerosis: A Case Report.
Michael M Messer, Irina V Haller. Innov Clin Neurosci 2017
Michael M Messer, Irina V Haller. Innov Clin Neurosci 2017
100
Regulation of neurotoxicity in the striatum and colon of MPTP-induced Parkinson's disease mice by gut microbiome.
Jiajing Shan, Youge Qu, Siming Wang, Yan Wei, Lijia Chang, Li Ma, Kenji Hashimoto. Brain Res Bull 2021
Jiajing Shan, Youge Qu, Siming Wang, Yan Wei, Lijia Chang, Li Ma, Kenji Hashimoto. Brain Res Bull 2021
100
Risk of psychosis after repeated intermittent administration of (S)-ketamine, but not (R)-ketamine, in mice.
Yunfei Tan, Kenji Hashimoto. J Affect Disord 2020
Yunfei Tan, Kenji Hashimoto. J Affect Disord 2020
100
Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studies.
Breno S Diniz, Meryl A Butters, Steven M Albert, Mary Amanda Dew, Charles F Reynolds. Br J Psychiatry 2013
Breno S Diniz, Meryl A Butters, Steven M Albert, Mary Amanda Dew, Charles F Reynolds. Br J Psychiatry 2013
100
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Nancy Diazgranados, Lobna Ibrahim, Nancy E Brutsche, Andrew Newberg, Phillip Kronstein, Sami Khalife, William A Kammerer, Zenaide Quezado, David A Luckenbaugh, Giacomo Salvadore,[...]. Arch Gen Psychiatry 2010
Nancy Diazgranados, Lobna Ibrahim, Nancy E Brutsche, Andrew Newberg, Phillip Kronstein, Sami Khalife, William A Kammerer, Zenaide Quezado, David A Luckenbaugh, Giacomo Salvadore,[...]. Arch Gen Psychiatry 2010
100
R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine.
Ji-Chun Zhang, Su-Xia Li, Kenji Hashimoto. Pharmacol Biochem Behav 2014
Ji-Chun Zhang, Su-Xia Li, Kenji Hashimoto. Pharmacol Biochem Behav 2014
100
Possible role of the gut microbiota-brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model.
Chun Yang, Youge Qu, Yuko Fujita, Qian Ren, Min Ma, Chao Dong, Kenji Hashimoto. Transl Psychiatry 2017
Chun Yang, Youge Qu, Yuko Fujita, Qian Ren, Min Ma, Chao Dong, Kenji Hashimoto. Transl Psychiatry 2017
100
Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease.
Hilary Grosso Jasutkar, Stephanie E Oh, M Maral Mouradian. Pharmacol Rev 2022
Hilary Grosso Jasutkar, Stephanie E Oh, M Maral Mouradian. Pharmacol Rev 2022
100
Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials.
Jin-Tai Yu, Wei Xu, Chen-Chen Tan, Sandrine Andrieu, John Suckling, Evangelos Evangelou, An Pan, Can Zhang, Jianping Jia, Lei Feng,[...]. J Neurol Neurosurg Psychiatry 2020
Jin-Tai Yu, Wei Xu, Chen-Chen Tan, Sandrine Andrieu, John Suckling, Evangelos Evangelou, An Pan, Can Zhang, Jianping Jia, Lei Feng,[...]. J Neurol Neurosurg Psychiatry 2020
100
Assessment of Ketamine and Its Enantiomers in an Organophosphate-Based Rat Model for Features of Gulf War Illness.
Jackie Zhu, Elisa Hawkins, Kristin Phillips, Laxmikant S Deshpande. Int J Environ Res Public Health 2020
Jackie Zhu, Elisa Hawkins, Kristin Phillips, Laxmikant S Deshpande. Int J Environ Res Public Health 2020
100
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Carlos A Zarate, Jaskaran B Singh, Paul J Carlson, Nancy E Brutsche, Rezvan Ameli, David A Luckenbaugh, Dennis S Charney, Husseini K Manji. Arch Gen Psychiatry 2006
Carlos A Zarate, Jaskaran B Singh, Paul J Carlson, Nancy E Brutsche, Rezvan Ameli, David A Luckenbaugh, Dennis S Charney, Husseini K Manji. Arch Gen Psychiatry 2006
100
Non-motor features of Parkinson disease.
Anthony H V Schapira, K Ray Chaudhuri, Peter Jenner. Nat Rev Neurosci 2017
Anthony H V Schapira, K Ray Chaudhuri, Peter Jenner. Nat Rev Neurosci 2017
100
Beneficial effects of (R)-ketamine, but not its metabolite (2R,6R)-hydroxynorketamine, in the depression-like phenotype, inflammatory bone markers, and bone mineral density in a chronic social defeat stress model.
Zhongwei Xiong, Yuko Fujita, Kai Zhang, Yaoyu Pu, Lijia Chang, Min Ma, Jincao Chen, Kenji Hashimoto. Behav Brain Res 2019
Zhongwei Xiong, Yuko Fujita, Kai Zhang, Yaoyu Pu, Lijia Chang, Min Ma, Jincao Chen, Kenji Hashimoto. Behav Brain Res 2019
100
Treatment response and age of onset as risk indicators for parkinson disease in patients with major depressive disorder: A nationwide longitudinal study.
Yee-Lam E Chan, Mu-Hong Chen, Ya-Mei Bai, Cheng Ta Li, Tzeng-Ji Chen, Tung-Ping Su. J Affect Disord 2021
Yee-Lam E Chan, Mu-Hong Chen, Ya-Mei Bai, Cheng Ta Li, Tzeng-Ji Chen, Tung-Ping Su. J Affect Disord 2021
100
Economic Burden of Multiple Sclerosis in Low- and Middle-Income Countries: A Systematic Review.
Jalal Dahham, Rana Rizk, Ingrid Kremer, Silvia M A A Evers, Mickaël Hiligsmann. Pharmacoeconomics 2021
Jalal Dahham, Rana Rizk, Ingrid Kremer, Silvia M A A Evers, Mickaël Hiligsmann. Pharmacoeconomics 2021
100
Antidepressant medications and osteoporosis.
R Rizzoli, C Cooper, J-Y Reginster, B Abrahamsen, J D Adachi, M L Brandi, O Bruyère, J Compston, P Ducy, S Ferrari,[...]. Bone 2012
R Rizzoli, C Cooper, J-Y Reginster, B Abrahamsen, J D Adachi, M L Brandi, O Bruyère, J Compston, P Ducy, S Ferrari,[...]. Bone 2012
100
R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects.
C Yang, Y Shirayama, J-c Zhang, Q Ren, W Yao, M Ma, C Dong, K Hashimoto. Transl Psychiatry 2015
C Yang, Y Shirayama, J-c Zhang, Q Ren, W Yao, M Ma, C Dong, K Hashimoto. Transl Psychiatry 2015
100
Osteoporosis after stroke: a review of the causes and potential treatments.
Stefano Carda, Carlo Cisari, Marco Invernizzi, Maurizio Bevilacqua. Cerebrovasc Dis 2009
Stefano Carda, Carlo Cisari, Marco Invernizzi, Maurizio Bevilacqua. Cerebrovasc Dis 2009
100
NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
Panos Zanos, Ruin Moaddel, Patrick J Morris, Polymnia Georgiou, Jonathan Fischell, Greg I Elmer, Manickavasagom Alkondon, Peixiong Yuan, Heather J Pribut, Nagendra S Singh,[...]. Nature 2016
Panos Zanos, Ruin Moaddel, Patrick J Morris, Polymnia Georgiou, Jonathan Fischell, Greg I Elmer, Manickavasagom Alkondon, Peixiong Yuan, Heather J Pribut, Nagendra S Singh,[...]. Nature 2016
100
Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine.
Kenji Hashimoto. Biochem Pharmacol 2020
Kenji Hashimoto. Biochem Pharmacol 2020
100
Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression.
Tung-Ping Su, Mu-Hong Chen, Cheng-Ta Li, Wei-Chen Lin, Chen-Jee Hong, Ralitza Gueorguieva, Pei-Chi Tu, Ya-Mei Bai, Chih-Ming Cheng, John H Krystal. Neuropsychopharmacology 2017
Tung-Ping Su, Mu-Hong Chen, Cheng-Ta Li, Wei-Chen Lin, Chen-Jee Hong, Ralitza Gueorguieva, Pei-Chi Tu, Ya-Mei Bai, Chih-Ming Cheng, John H Krystal. Neuropsychopharmacology 2017
100
Antidepressant effects of ketamine in depressed patients.
R M Berman, A Cappiello, A Anand, D A Oren, G R Heninger, D S Charney, J H Krystal. Biol Psychiatry 2000
R M Berman, A Cappiello, A Anand, D A Oren, G R Heninger, D S Charney, J H Krystal. Biol Psychiatry 2000
100
Brain-gut-microbiota axis in depression: A historical overview and future directions.
Lijia Chang, Yan Wei, Kenji Hashimoto. Brain Res Bull 2022
Lijia Chang, Yan Wei, Kenji Hashimoto. Brain Res Bull 2022
100
Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent repeated intermittent administration of (R)-ketamine, but not (S)-ketamine: Role of BDNF-TrkB signaling.
Yunfei Tan, Yuko Fujita, Youge Qu, Lijia Chang, Yaoyu Pu, Siming Wang, Xingming Wang, Kenji Hashimoto. Pharmacol Biochem Behav 2020
Yunfei Tan, Yuko Fujita, Youge Qu, Lijia Chang, Yaoyu Pu, Siming Wang, Xingming Wang, Kenji Hashimoto. Pharmacol Biochem Behav 2020
100
Targeting the gut to treat multiple sclerosis.
Laura Ghezzi, Claudia Cantoni, Gabriela V Pinget, Yanjiao Zhou, Laura Piccio. J Clin Invest 2021
Laura Ghezzi, Claudia Cantoni, Gabriela V Pinget, Yanjiao Zhou, Laura Piccio. J Clin Invest 2021
100
Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval.
Erick H Turner. Lancet Psychiatry 2019
Erick H Turner. Lancet Psychiatry 2019
100
The cuprizone model for demyelination.
O Torkildsen, L A Brunborg, K-M Myhr, L Bø. Acta Neurol Scand Suppl 2008
O Torkildsen, L A Brunborg, K-M Myhr, L Bø. Acta Neurol Scand Suppl 2008
100
Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study.
Jaskaran B Singh, Maggie Fedgchin, Ella Daly, Liwen Xi, Caroline Melman, Geert De Bruecker, Andre Tadic, Pascal Sienaert, Frank Wiegand, Husseini Manji,[...]. Biol Psychiatry 2016
Jaskaran B Singh, Maggie Fedgchin, Ella Daly, Liwen Xi, Caroline Melman, Geert De Bruecker, Andre Tadic, Pascal Sienaert, Frank Wiegand, Husseini Manji,[...]. Biol Psychiatry 2016
100
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.